Molecular pathology

Philips suite of artificial intelligence applications help drive accuracy and efficiencies in your molecular program

Looking for more information?

Find out more about Philips products in molecular pathology


Molecular pathology is becoming increasingly important due to an increase in the demand for personalized, targeted therapies. 


As demand for the molecular profiling of solid tumors increases, so too does the need for H&E sample review, annotation and tumor content assessment. This is placing extra workload on already stretched pathology departments.

General pathology workflows can be complicated and fragmented and molecular pathology workflows are often no different. Additionally, molecular pathology faces other fundamental challenges, including the provision of accurate tumor assessment for downstream molecular tests that is well documented in literature.1


All molecular tests (such as EGFR or NGS) require a minimum percentage of tumor cells due to their minimal sensitivity levels. Accurate information on tumor cell percentage therefore, is essential in having confidence in the selection for personalized medicine. 

molecular checking image

Without sufficient tumor cells and associated tumor DNA, the chances of finding important molecular test outcomes are significantly reduced and some molecular tests may deliver a false negative result.  


Similarly, insufficient total cell numbers, may result in a failed sample run leading to extra consumable and staff costs. In fact, evidence shows that molecular biomarker trials are failing, in some cases by as much as 38%, due to the inability to reliably perform molecular testing after poorly chosen tissue samples.2


decrease in molecular biomarker trials
molecular shape image

Analyze solid tumor tissue samples therefore, quickly to enhance the quality and accuracy of macrodissection, nucleic acid extraction, and molecular profiling using Philips TissueMark. 


TissueMark is a key offering in Philips computational pathology portfolio that assists the user to examine the region of interest (ROI) for Macrodissection by utilizing artificial intelligence through deep learning programs in order to:


  •  Visualize the ROI and
  •  Indicate the estimated cellular profile within the ROI 

Key benefits


Improve the quality of molecular tests with accurate ROI and cellularity guidance 

search molecular image
Validated macrodissection boundaries
molecular identifying image
Identify insufficient samples with accurate cellularity guidance
High throuhput instuitive workflow
quality assessment image
High throughput sample quality assessment 
case management image
Easy case management, case organisation and viewing leading to time savings 
molecular cloud image
Remote review for experts



Oncotarget PDF - Automated tumor analysis for molecular profiling in lung cancer - Download now

  1. Automated tumor analysis for molecular profiling in lung cancer, P. Hamilton et al, Oncotarget. (2015)
  2. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate - https://www.ncbi.nlm.nih.gov/pubmed/23887293
  3. TissueMark is not intended for diagnostic, monitoring or therapeutic purposes or in any other manner for regular medical practice.
  4. The Philips IntelliSite Pathology Solution has obtained market access clearance as IVD for primary diagnosis in approx. 50 countries, such as EEA (European Economic Area), USA, Canada, Japan, South Korea, and other countries in Asia, Middle East and South America.

Contact information

* This field is mandatory
By specifying your reason for contact we will be able to provide you with a better service.